Vermont Primary Care Provider Perspectives on Psychedelics - A Cross-Sectional Study

Abstract

The medical utility of psychedelics has been the subject of significant scientific interest in recent years. While most of these substances remain Schedule I under the Controlled Substances Act, advancements in research have led states to consider expanding legal access, impacting primary care, where patients often seek mental health support and treatment. In July 2023 we conducted a cross-sectional survey of 770 Vermont primary care providers (PCPs) about their familiarity and concerns with psychedelics, as well as opinions on access and therapeutic value (response rate 17%). Two-thirds of respondents reported familiarity with psychedelics being used therapeutically, but less than half were aware of current regulatory statuses of LSD, psilocybin, and MDMA. Ninety-six percent were neutral or agreed that psychedelics have high therapeutic potential. The highest concerns were effects on youth, potential for psychosis, and traffic safety. Eighty-three percent were not at all or only slightly concerned about the inherent dangers of psychedelics. Seventy-seven percent were interested in further education. Overall, PCPs in Vermont, a state considering changes in access to psilocybin, are familiar with psychedelics, and cautiously optimistic about their therapeutic role. As research develops, it is important to incorporate resultant changes in policy and medicine into PCP continuing education.

Keywords: Psychedelics; education; hallucinogens; mental disorders; therapeutic use.